A Post-market Observational Study With the easyEndoTM Universal Linear Cutting Stapler in Standard Laparoscopic and Robot-assisted Laparoscopic Roux-en-Y Gastric Bypass (RYGB) Surgery

Obesity Clinical Trial

— SIRIUS  

Official title:

A Post-market Observational Study With the easyEndoTM Universal Linear Cutting Stapler in Standard Laparoscopic and Robot-assisted Laparoscopic Roux-en-Y Gastric Bypass (RYGB) Surgery

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04543526
• Other study ID #: DM-ZOL-01
• Status: Withdrawn
• Start date: September 1, 2021
• Est. completion date: November 30, 2024

Study information

• Verified date: July 2021
• Source: Duomed
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary purpose of this observational registry is to evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads from Ezisurg Medical when used to create anastomoses during standard and robot-assisted laparoscopic Roux-en-Y Gastric Bypass (RYGB) surgery. Stapler performance during surgery as well as post-operative pain and the clinical efficacy of the procedures will be determined as secondary objectives.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 30, 2024
• Est. primary completion date: October 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient = 18 years of age at study entry.
• Patient and investigator signed and dated the informed consent form prior to the index-procedure.
• Patient has a BMI = 35 kg/m2 with one or more related co-morbidity.
• Patient has a BMI = 40 kg/m2.
• Patient is eligible for standard laparoscopic or for robotic-assisted laparoscopic RYGB surgery.

Exclusion Criteria:

• Patient is unable / unwilling to provide informed consent.
• Patient has a history of bariatric surgery.
• Patient is unable to comply with the study protocol or proposed follow-up visits.
• Patient has a contra-indication for standard laparoscopic or robot-assisted laparoscopic RYGB surgery.

Related Conditions & MeSH terms

• Obesity
• Roux-en-Y Gastric Bypass

Intervention

Device:
• easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creating anastomoses during standard and robot-assisted laparoscopic RYGB, manufactured by Ezisurg Medical.

Locations

Country	Name	City	State
Belgium	Ziekenhuis Oost-Limburg (ZOL)	Genk
Belgium	Ziekenhuis Maas en Kempen (ZMK)	Maaseik

Sponsors (1)

Lead Sponsor	Collaborator
Duomed

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety - Conversion rate to laparotomy	Number of conversions to laparotomy during the index procedure	At index procedure.
Primary	Safety - Length of stay at the intensive care unit	Number of days at the intensive care unit after the index procedure.	At index procedure.
Primary	Safety - Length of stay in the hospital by the modified Post-Anesthesia Discharge Scoring System (PADSS)	The Modified PADSS guarantees safe discharge. PADSS is based on the assessment of 6 criteria: vital signs (including blood pressure, pulse, temperature and respiratory rate), ambulation, nausea / vomiting, pain, surgical bleeding and fluid intake / output. Each criterion is given a score from 0 to 2. Patients scoring = 9 are considered fit for discharge, provided that the score for vital signs is not lower than 2 and that none of the other five criteria is 0, even if the total score reaches 9.	At index procedure.
Primary	Safety - Number of re-interventions and number of participants with (serious) adverse events	Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo.	At index procedure.
Primary	Safety - Length of stay at the intensive care unit.	Number of days at the intensive care unit after the index procedure.	At discharge, up to 1 week.
Primary	Safety - Length of stay in the hospital by the modified Post-Anesthesia Discharge Scoring System (PADSS)	he Modified PADSS guarantees safe discharge. PADSS is based on the assessment of 6 criteria: vital signs (including blood pressure, pulse, temperature and respiratory rate), ambulation, nausea / vomiting, pain, surgical bleeding and fluid intake / output. Each criterion is given a score from 0 to 2. Patients scoring = 9 are considered fit for discharge, provided that the score for vital signs is not lower than 2 and that none of the other five criteria is 0, even if the total score reaches 9.	At discharge, up to 1 week.
Primary	Safety - Number of re-interventions and number of participants with (serious) adverse events	Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo.	At discharge, up to 1 week.
Primary	Safety - Number of re-interventions and number of participants with (serious) adverse events	Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo.	Follow-up 1: 1 month after the procedure.
Primary	Safety - Number of re-interventions and number of participants with (serious) adverse events	Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo.	Follow-up 2: 6 months after the procedure.
Primary	Safety - Number of re-interventions and number of participants with (serious) adverse events	Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo.	Follow-up 3: 12 months after the procedure
Primary	Safety - Number of re-interventions and number of participants with (serious) adverse events	Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo.	Follow-up 4: 24 months after the procedure.
Secondary	Device performance - Technical success of the surgical procedure performed with the device	Number of procedures with technical success defined as bariatric surgery as intended, without technical difficulties and without conversion to laparotomy.	At index procedure
Secondary	Device performance - Scoring of operator satisfaction	Scoring of: easy of intra-abdominal device positioning, grasping/climbing force, sharpness of the blades, staple-line formation, device stability, device maneuverability, battery power, device consistency and reliability, ergonomic design, hemostasis. Each of the aforementioned items receives a score from 0 to 4, with 0 indicating that the user is very unsatisfied and 4 indicating that the user is very satisfied.	At index procedure
Secondary	Post-operative pain by means of the Visual Analogue Scale (VAS)	Assessment of acute post-operative abdominal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain.	At index procedure
Secondary	Post-operative pain by means of the Visual Analogue Scale (VAS)	Assessment of acute post-operative abdominal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain.	At discharge, up to 1 week
Secondary	Post-operative pain by means of the Visual Analogue Scale (VAS)	Assessment of the worst post-operative abdominal pain since discharge by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain.	Follow-up 1: 1 month after the procedure
Secondary	Post-operative food tolerance by means of the food tolerance questionnaire	Food tolerance by means of the food tolerance questionnaire. The food tolerance questionnaire allows to score the patients' satisfaction regarding food intake and food tolerance after bariatric surgery. The patients' interpretation of food intake is scored between 1 (very poor) and 5 (excellent). A cumulative score, varying between 1 and 27 is derived, with 27 representing an excellent food tolerance.	Follow-up 1: 1 month after the procedure
Secondary	Post-operative food tolerance by means of the food tolerance questionnaire	Food tolerance by means of the food tolerance questionnaire. The food tolerance questionnaire allows to score the patients' satisfaction regarding food intake and food tolerance after bariatric surgery. The patients' interpretation of food intake is scored between 1 (very poor) and 5 (excellent). A cumulative score, varying between 1 and 27 is derived, with 27 representing an excellent food tolerance.	Follow-up 2: 6 months after the procedure
Secondary	Post-operative food tolerance by means of the food tolerance questionnaire	Food tolerance by means of the food tolerance questionnaire. The food tolerance questionnaire allows to score the patients' satisfaction regarding food intake and food tolerance after bariatric surgery. The patients' interpretation of food intake is scored between 1 (very poor) and 5 (excellent). A cumulative score, varying between 1 and 27 is derived, with 27 representing an excellent food tolerance.	Follow-up 3: 12 months after the procedure
Secondary	Post-operative food tolerance by means of the food tolerance questionnaire	Food tolerance by means of the food tolerance questionnaire. The food tolerance questionnaire allows to score the patients' satisfaction regarding food intake and food tolerance after bariatric surgery. The patients' interpretation of food intake is scored between 1 (very poor) and 5 (excellent). A cumulative score, varying between 1 and 27 is derived, with 27 representing an excellent food tolerance.	Follow-up 4: 24 months after the procedure
Secondary	Post-operative change in weight	Weight loss 1 month after the surgical procedure as compared to the patients' weight at baseline.	Follow-up 1: 1 month after the procedure
Secondary	Post-operative change in weight	Weight loss 6 months after the surgical procedure as compared to the patients' weight at baseline.	Follow-up 2: 6 months after the procedure
Secondary	Post-operative change in weight	Weight loss 12 months after the surgical procedure as compared to the patients' weight at baseline.	Follow-up 3: 12 months after the procedure
Secondary	Post-operative change in weight	Weight loss 24 months after the surgical procedure as compared to the patients' weight at baseline.	Follow-up 4: 24 months after the procedure
Secondary	Number of participants with a post-operative change of cormorbidities	Comorbidities (diabetes mellitus, peripheral arterial disease, coronary arterial disease, sleep disordered breathing, hypertension, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, asthma, congestive heart failure, degenerative joint disease, gastroesophageal reflux, chronic obstructive pulmonary disease, use of immunosuppressants) 12 months after the surgical procedure as compared to the patients' comorbidities at baseline.	Follow-up 3: 12 months after the procedure
Secondary	Number of participants with a post-operative change of cormorbidities	Comorbidities (diabetes mellitus, peripheral arterial disease, coronary arterial disease, sleep disordered breathing, hypertension, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, asthma, congestive heart failure, degenerative joint disease, gastroesophageal reflux, chronic obstructive pulmonary disease, use of immunosuppressants) 24 months after the surgical procedure as compared to the patients' comorbidities at baseline.	Follow-up 4: 24 months after the procedure